Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Deloitte
Federal Trade Commission
Harvard Business School
Accenture
Citi
QuintilesIMS
Teva
Medtronic

Generated: December 10, 2018

DrugPatentWatch Database Preview

Litigation Details for NeuroGrafix v. The Regents of the University of California (C.D. Cal. 2011)

« Back to Dashboard

NeuroGrafix v. The Regents of the University of California (C.D. Cal. 2011)

Docket ➤ Sign Up Date Filed 2011-09-14
Court District Court, C.D. California Date Terminated 2012-12-17
Cause 35:271 Patent Infringement Assigned To Mariana R. Pfaelzer
Jury Demand Both Referred To Ralph Zarefsky
Parties GENERAL ELECTRIC COMPANY; IMAGE-BASED SURGICENTER CORPORATION; NEUROGRAFIX; NEUROGRAPHY INSTITUTE MEDICAL ASSOCIATES INC; PHILIPS ELECTRONIC NORTH AMERICA CORPORATION; REGENTS OF THE UNIVERSITY OF CALIFORNIA; WASHINGTON RESEARCH FOUNDATION
Patents 10,041,044
Attorneys Adam S Hoffman; Alexander C D Giza; Ali R Sharifahmadian; Andrew David Weiss; Bradley W Gunning; Brian Martinez; Carolyn C Chang; Cliff Allan Maier; Fredricka Ung; Heather N Mewes; Jeffrey Virnelson Lasker; Jennifer Anne Sklenar; Jennifer Jane Johnson; Jennifer T Lorch; Marc A Cohn; Marc A Fenster; Matthew M Wolf; Meredith L Erdman; Michael A Molano; Michael Elliot Ginsberg
Firms Fenwick & West LLP; Fenwick and West; Fenwick and West LLP; Meredith L Erdman
Link to Docket External link to docket
Biologic Drugs cited in NeuroGrafix v. The Regents of the University of California
The biologic drug covered by the patent cited in this case is ➤ Sign Up .

Details for NeuroGrafix v. The Regents of the University of California (C.D. Cal. 2011)

Date Filed Document No. Description Snippet Link To Document
2012-05-14 74 Exhibit 10 arrangement arrangement means . . .”: ’360 patent 10:41-44; electromagnetic responsiveness of … selected structure from other ’360 Patent 9:64-10:16; 11:9-18; 11:46-49; … tissue]/[selected structure], thereby ’360 Patent 9:64-10:16; 11:9-18; 11:46- 49; representative … ‘360 patent at 13:3-6 (“As will be described in …, an arrangement of diffusion- ‘360 patent 15:51-62; 16:34-47; Fig. 10, blocks diffusion-weighted External link to document
Date Filed Document No. Description Snippet Link To Document

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Fish and Richardson
Moodys
Chinese Patent Office
Mallinckrodt
QuintilesIMS
Citi
US Department of Justice
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.